Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Cash Flow (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Net Cash Flow for 16 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 632.76% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.5 million through Dec 2025, up 47.55% year-over-year, with the annual reading at -$17.5 million for FY2025, 47.55% up from the prior year.
  • Net Cash Flow hit $14.8 million in Q4 2025 for Vanda Pharmaceuticals, up from -$10.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $219.1 million in Q1 2023 to a low of -$204.1 million in Q2 2023.
  • Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of -$4.7 million in 2021.
  • Biggest five-year swings in Net Cash Flow: surged 5078.73% in 2022 and later crashed 2224.23% in 2023.
  • Year by year, Net Cash Flow stood at $1.6 million in 2021, then soared by 5078.73% to $85.4 million in 2022, then plummeted by 155.61% to -$47.5 million in 2023, then surged by 104.25% to $2.0 million in 2024, then skyrocketed by 632.76% to $14.8 million in 2025.
  • Business Quant data shows Net Cash Flow for VNDA at $14.8 million in Q4 2025, -$10.8 million in Q3 2025, and -$30.9 million in Q2 2025.